We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the... Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States. Show more
REDWOOD CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.ย (โCoherus,โ NASDAQ: CHRS) today announced that senior management will present at the 43rd Annual J.P. Morgan...
- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.04 | -2.66666666667 | 1.5 | 1.6 | 1.435 | 1574934 | 1.45857328 | CS |
4 | -0.14 | -8.75 | 1.6 | 1.7699 | 1.35 | 2066935 | 1.50122027 | CS |
12 | 0.6485 | 79.9137399877 | 0.8115 | 2.43 | 0.6603 | 5274319 | 1.42799139 | CS |
26 | -0.2 | -12.0481927711 | 1.66 | 2.43 | 0.6603 | 3564026 | 1.35006232 | CS |
52 | -1.06 | -42.0634920635 | 2.52 | 2.97 | 0.6603 | 3055095 | 1.70577885 | CS |
156 | -12.61 | -89.6233120114 | 14.07 | 14.11 | 0.6603 | 2525805 | 3.77974828 | CS |
260 | -18.47 | -92.6743602609 | 19.93 | 23.03 | 0.6603 | 1917919 | 6.61182218 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions